Aravive Inc
F:VE11
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Aravive Inc
F:VE11
|
US |
|
B
|
Biotoxtech Co Ltd
KOSDAQ:086040
|
KR |
|
A
|
Advancecon Holdings Bhd
KLSE:ADVCON
|
MY |
|
F
|
FoodNamoo Inc
KOSDAQ:290720
|
KR |
|
R
|
Remote Dynamics Inc
OTC:RMTD
|
US |
|
LifeWorks Inc
TSX:LWRK
|
CA |
|
S
|
Sichuan Furong Technology Co Ltd
SSE:603327
|
CN |
|
Fortune Indonesia Tbk PT
IDX:FORU
|
ID |
|
Egetis Therapeutics AB (publ)
STO:EGTX
|
SE |
|
TransAlta Corp
TSX:TA
|
CA |
|
Adaptive Biotechnologies Corp
NASDAQ:ADPT
|
US |
Aravive Inc
Aravive, Inc. operates as a clinical stage biotechnology company. The company is headquartered in Houston, Texas and currently employs 23 full-time employees. The company went IPO on 2014-03-20. The firm is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. Its lead product candidate, AVB-500, is an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth, tumor metastasis, resistance to treatment, and decreased survival. The firm is evaluating AVB-500 in a registrational Phase III trial in platinum resistant ovarian cancer, a Phase Ib/2 trial in second line plus, clear cell renal cell carcinoma (ccRCC), and a Phase Ib/2 trial in first-line treatment of pancreatic adenocarcinoma. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. The company is a Fc-fusion protein designed to block the activation of the growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL.
Aravive, Inc. operates as a clinical stage biotechnology company. The company is headquartered in Houston, Texas and currently employs 23 full-time employees. The company went IPO on 2014-03-20. The firm is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. Its lead product candidate, AVB-500, is an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth, tumor metastasis, resistance to treatment, and decreased survival. The firm is evaluating AVB-500 in a registrational Phase III trial in platinum resistant ovarian cancer, a Phase Ib/2 trial in second line plus, clear cell renal cell carcinoma (ccRCC), and a Phase Ib/2 trial in first-line treatment of pancreatic adenocarcinoma. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. The company is a Fc-fusion protein designed to block the activation of the growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL.
